Author:
Li Liangping,Huang Zetian,Huang Yuying,Li Yongkun,Ma Xuesong,Li Pingping,Du Wenqing,Wang Hui,Zhao Yufei,Zeng Shulan,Peng Yan,Zhang Guohai
Funder
Guangxi Natural Science Foundation
Reference37 articles.
1. Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders;Yamamoto;Chem. Soc. Rev.,2022
2. ARID2 is a pomalidomide-dependent CRL4 (CRBN) substrate in multiple myeloma cells;Yamamoto;Nat. Chem. Biol.,2020
3. Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer;Lee;Lung Cancer,2008
4. Gefitinib combined with thalidomide as the first line treatment against advanced pulmonary adenocarcinoma with EGFR mutation;Chen;China J. Hosp. Pharm.,2017
5. Randomized study of thalidomide combined with vinorelbine and cisplatin chemotherapy for the treatment of advanced non-small cell lung cancer;Gu;Zhonghua Zhong Liu Za Zhi,2009